Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Schering-Plough extends antibody alliance with MorphoSys until 2010

June 17, 2009

Roche selects rHuPH20 as fifth exclusive target under license agreement with Halozyme

June 10, 2009

Raptor and Roche sign collaboration agreement for therapeutic delivery across BBB

June 10, 2009

Centocor signs 5-year CRADA with NCI to develop novel cell therapies to treat cancer

June 9, 2009

Chugai and Gene Bridges expand license agreement for Red/ET recombineering technology

May 28, 2009

Celator and Cephalon enter agreement in drug development and life-cycle management

May 25, 2009

Asubio chooses Genedata's Expressionist to manage DNA array and molecular profiling data

May 20, 2009

Alnylam and Isis sign licensing and collaboration agreement to develop ssRNAi technology

April 30, 2009

Novimmune designs antibodies with multiple specificities

April 20, 2009

Ensemble forms alliance with Bristol-Myers Squibb to develop novel drug class

April 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...